Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Operations (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Cash from Operations for 16 consecutive years, with 44891000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 36.66% year-over-year to 44891000.0, compared with a TTM value of 208670000.0 through Dec 2025, down 12.98%, and an annual FY2025 reading of 208670000.0, down 12.98% over the prior year.
  • Cash from Operations was 44891000.0 for Q4 2025 at Catalyst Pharmaceuticals, up from 32438000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 72871000.0 in Q3 2024 and bottomed at 3814000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 38424850.0, with a median of 36257500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations skyrocketed 164.5% in 2024, then plummeted 55.49% in 2025.
  • Year by year, Cash from Operations stood at 19176000.0 in 2021, then soared by 109.0% to 40077000.0 in 2022, then skyrocketed by 38.85% to 55648000.0 in 2023, then increased by 27.37% to 70877000.0 in 2024, then plummeted by 36.66% to 44891000.0 in 2025.
  • Business Quant data shows Cash from Operations for CPRX at 44891000.0 in Q4 2025, 32438000.0 in Q3 2025, and 71298000.0 in Q2 2025.